ex scientia, Sumitomo Dainippon deal

ex scientia met a milestone under a November 2014 deal with Sumitomo’s Sunovion Pharmaceuticals Inc. subsidiary to discover and optimize multi-target small molecule candidates to treat psychiatric dis...